Paksons Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
as on 15-11-2024
- Paid Up Capital ₹ 0.96 M
as on 15-11-2024
- Company Age 26 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.66 Cr
as on 15-11-2024
- Revenue -19.22%
(FY 2023)
- Profit -56.53%
(FY 2023)
- Ebitda -45.55%
(FY 2023)
- Net Worth 23.13%
(FY 2023)
- Total Assets -3.24%
(FY 2023)
About Paksons Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 0.96 M.
The company currently has active open charges totaling ₹1.66 Cr.
Sushil Aggarwal and Sumit Aggarwal serve as directors at the Company.
- CIN/LLPIN
U74899DL1998PTC092394
- Company No.
092394
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Feb 1998
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Paksons Pharmaceuticals Private Limited offer?
Paksons Pharmaceuticals Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Injection.
Who are the key members and board of directors at Paksons Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumit Aggarwal  | Director | 15-Nov-2002 | Current |
| Sushil Aggarwal | Director | 23-Feb-1998 | Current |
Financial Performance of Paksons Pharmaceuticals.
Paksons Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 19.22% decrease. The company also saw a substantial fall in profitability, with a 56.53% decrease in profit. The company's net worth Soared by an impressive increase of 23.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Paksons Pharmaceuticals?
In 2023, Paksons Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 Sep 2022 | ₹0.94 M | Open |
Others Creation Date: 29 Aug 2022 | ₹1.50 M | Open |
Others Creation Date: 07 Feb 2017 | ₹0.60 M | Open |
How Many Employees Work at Paksons Pharmaceuticals?
Paksons Pharmaceuticals has a workforce of 8 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Paksons Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Paksons Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
